Sjogren’s officially recognised as a disease

It’s official, Sjogren’s Syndrome is now recognised globally as Sjogren’s Disease.

The renaming acknowledges the longstanding understanding among patients and specialists that this condition is a systemic autoimmune disease, rather than merely a vague compilation of symptoms. Previously regarded as an adjunct to lupus or rheumatoid arthritis, Sjogren’s has frequently been marginalised in the management of connective tissue diseases. It has often been treated in a similar manner but seldom afforded equal significance. This move marks a step toward balance.

As we put it in our feature “Sjogren’s: The Moth Amongst the Butterflies”, it’s long been the black sheep of systemic autoimmune diseases. Under-recognised, under-researched and often misdiagnosed. The shift from “syndrome” to “disease” changes that. It acknowledges that Sjogren’s carries its own distinct pathology, its own risks and deserves the same clinical seriousness as its more familiar counterparts.

In Practice:

The term “disease” carries medical authority, potentially helping drive earlier diagnosis, better research funding, and fairer access to care.

For patients, it brings validation and carries the message that this isn’t an accessory condition or afterthought.

It may help shift clinical guidelines and prioritisation for specialist referral and treatment planning.

Don’t expect overnight change

The global adoption of “Sjogren’s Disease” won’t filter through immediately to NHS settings. Expect to see the shift appear first in Rheumatology and Immunology circles, gradually influencing clinical language and coding in the years ahead.

Still, this is a major step forward. Recognition matters and this one’s been a long time coming.

Back to home